Investigation of possible interference of a metabolite of etoricoxib (Arcoxia®) in the detection of 16a-hydroxyprednisolone by LC-MS/MS

dc.contributor.authorSaardpun Nen_US
dc.contributor.authorPanan Sen_US
dc.contributor.authorWilairat Pen_US
dc.contributor.authorChaikum Nen_US
dc.contributor.otherMahidol University. National Doping Control Centreen_US
dc.date.accessioned2019-07-03T01:54:32Z
dc.date.available2019-07-03T01:54:32Z
dc.date.created2019-06-28
dc.date.issued2014
dc.descriptionRecent Advances in Doping Analysis (21) Proceedings of the Manfred Donike Workshop 31th Cologne Workshop on Dope Analysis 24th February to 1st March 2013, Page 117-120en_US
dc.description.abstractEtoricoxib (Arcoxia®) is a recent drug for the effective treatment of pain, inflammation and fever. It is available without prescription in Thailand but may require a physician’s prescription in other countries. This investigation was initiated by the presence of a large peak in about 10% of the MRM chromatograms of our screening procedure for corticosteroids by LC-MS/MS. This peak was in the time window of the MRM transition for 16a-hydroxyprednisolone. Fortunately for some of these samples the data sheet for previous use of medication stated the use of Arcoxia®. To confirm that the interfering peak was due to a metabolite of the drug etoricoxib (Arcoxia®) an excretion study of a male volunteer who had taken a 30-mg single oral dose of etoricoxib was performed. Metabolites of the drug were identified by comparison of the observed mass spectra (both full scan and product ion scan) with that reported in the literature. It was shown that the interference peak was 6’-hydroxymethyl-etoricoxib. The mass spectrum information of this metabolite was then used to modify the MRM transition for 16a-hydroxyprednisolone in the screening method.en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/44212
dc.language.isoengen_US
dc.rightsMahidol Universityen_US
dc.rights.holderNational Doping Control Centre Mahidol Universityen_US
dc.subjectEtoricoxib (Arcoxia®)en_US
dc.subjectmetaboliteen_US
dc.subject16a-hydroxyprednisoloneen_US
dc.subjectLC-MS/MSen_US
dc.titleInvestigation of possible interference of a metabolite of etoricoxib (Arcoxia®) in the detection of 16a-hydroxyprednisolone by LC-MS/MSen_US
dc.typeProceeding Posteren_US
mods.location.urlhttps://drive.google.com/file/d/1JBuY-suwNXhUabe0dnF1sLhM85vgQzrC/view

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
dc-pc-prapin-2014-1.pdf
Size:
556.92 KB
Format:
Adobe Portable Document Format

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: